When biopharmaceutical company Achaogen filed for bankruptcy in April, antibiotic development advocates warned that the move was an ominous sign for the antibiotic market.
The previous June, the US Food and Drug Administration (FDA) had approved plazomicin, Achaogen’s antibiotic for treatment of complicated urinary tract infections. The drug was viewed as an important new tool for carbapenem-resistant Enterobacteriaceae (CRE) infections, which are among the most difficult bacterial infections to treat. The company also had other new antibiotic candidates in its pipeline.
Read more at CIDRAP…
Oct 7 Antimicrob Agents Chemother abstract
Oct 8 Ann Intern Med abstract
Jul 28 Open Forum Infect Dis study
Aug 8 Philadelphia Inquirer commentary
Apr 16 CIDRAP News story, “Achaogen bankruptcy raises worry over antibiotic pipeline“